Published in Gut on April 01, 2006
Assessment of hepatic fibrosis with magnetic resonance elastography. Clin Gastroenterol Hepatol (2007) 5.77
Early detection of nonalcoholic steatohepatitis in patients with nonalcoholic fatty liver disease by using MR elastography. Radiology (2011) 1.80
qFibrosis: a fully-quantitative innovative method incorporating histological features to facilitate accurate fibrosis scoring in animal model and chronic hepatitis B patients. J Hepatol (2014) 1.77
Non-invasive markers for hepatic fibrosis. BMC Gastroenterol (2011) 1.65
Assessment of chronic hepatitis and fibrosis: comparison of MR elastography and diffusion-weighted imaging. AJR Am J Roentgenol (2011) 1.62
Non-invasive assessment of liver fibrosis. Ann Gastroenterol (2012) 1.07
Non-invasive detection of liver fibrosis: MR imaging features vs. MR elastography. Abdom Imaging (2015) 0.98
Liver Shear-Wave Velocity and Serum Fibrosis Markers to Diagnose Hepatic Fibrosis in Patients with Chronic Viral Hepatitis B. Korean J Radiol (2016) 0.91
The relationship between transient elastography and histological collagen proportionate area for assessing fibrosis in chronic viral hepatitis. J Gastroenterol (2012) 0.90
Noninvasive assessment of liver damage in chronic hepatitis B. World J Hepatol (2013) 0.86
Fibroscan for assessing liver fibrosis: An acceptable alternative for liver biopsy: Fibroscan: an acceptable alternative for liver biopsy. Hepat Mon (2011) 0.84
Transjugular liver biopsy. Semin Intervent Radiol (2012) 0.83
A specific gene-expression signature quantifies the degree of hepatic fibrosis in patients with chronic liver disease. World J Gastroenterol (2007) 0.82
CUG-binding protein 1 regulates HSC activation and liver fibrogenesis. Nat Commun (2016) 0.81
Magnetic Resonance Elastography for the Evaluation of Liver Fibrosis in Chronic Hepatitis B and C by Using Both Gradient-Recalled Echo and Spin-Echo Echo Planar Imaging: A Prospective Study. Am J Gastroenterol (2016) 0.81
Ischemia-modified albumin levels in children with chronic liver disease. Gut Liver (2012) 0.81
Automated biphasic morphological assessment of hepatitis B-related liver fibrosis using second harmonic generation microscopy. Sci Rep (2015) 0.81
Micro soft tissues visualization based on x-ray phase-contrast imaging. Open Med Inform J (2011) 0.81
Nutrigenomics analysis reveals that copper deficiency and dietary sucrose up-regulate inflammation, fibrosis and lipogenic pathways in a mature rat model of nonalcoholic fatty liver disease. J Nutr Biochem (2015) 0.81
Development of a computational high-throughput tool for the quantitative examination of dose-dependent histological features. Toxicol Pathol (2014) 0.80
Non-invasive index for predicting significant liver fibrosis: comparison of diagnostic performances in patients with chronic hepatitis B and C. Dig Dis Sci (2010) 0.80
Multiplex protein analysis to determine fibrosis stage and progression in patients with chronic hepatitis C. Clin Gastroenterol Hepatol (2014) 0.79
Characterising the association of latency with α(1)-antitrypsin polymerisation using a novel monoclonal antibody. Int J Biochem Cell Biol (2014) 0.78
Sparse logistic regression for diagnosis of liver fibrosis in rat by using SCAD-penalized likelihood. J Biomed Biotechnol (2011) 0.78
Head-to-Head Comparison between Collagen Proportionate Area and Acoustic Radiation Force Impulse Elastography in Liver Fibrosis Quantification in Chronic Hepatitis C. PLoS One (2015) 0.77
MR Elastography of Liver Disease: State of the Art. Appl Radiol (2013) 0.77
Continuous Grading of Early Fibrosis in NAFLD Using Label-Free Imaging: A Proof-of-Concept Study. PLoS One (2016) 0.77
Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity. Radiology (2016) 0.77
Non-invasive Markers of Liver Fibrosis: Adjuncts or Alternatives to Liver Biopsy? Front Pharmacol (2016) 0.76
Quantitative BOLD imaging at 3T: Temporal changes in hepatocellular carcinoma and fibrosis following oxygen challenge. J Magn Reson Imaging (2016) 0.76
Histochemical Detection of Collagen Fibers by Sirius Red/Fast Green Is More Sensitive than van Gieson or Sirius Red Alone in Normal and Inflamed Rat Colon. PLoS One (2015) 0.76
Comparison of collagen proportionate areas in liver fibrosis quantification between chronic hepatitis B and C. Medicine (Baltimore) (2016) 0.75
2D Shear Wave Elastography of Liver in Patients with Primary Extrahepatic Portal Vein Obstruction. J Clin Exp Hepatol (2016) 0.75
Comparison of Histochemical Stainings in Evaluation of Liver Fibrosis and Correlation with Transient Elastography in Chronic Hepatitis. Anal Cell Pathol (Amst) (2015) 0.75
Magnetic resonance elastography in a rabbit model of liver fibrosis: a 3-T longitudinal validation for clinical translation. Am J Transl Res (2016) 0.75
Hepatic steatosis and fibrosis: Non-invasive assessment. World J Gastroenterol (2016) 0.75
Non-biopsy methods to determine hepatic fibrosis. J Med Life (2010) 0.75
Viscoelastic parameters for quantifying liver fibrosis: three-dimensional multifrequency MR elastography study on thin liver rat slices. PLoS One (2014) 0.75
A systematic and quantitative method for wound-dressing evaluation. Burns Trauma (2015) 0.75
Current and emerging surrogate markers of hepatic fibrosis in primary biliary cirrhosis. Liver Int (2008) 0.75
Evaluation of liver fibrosis: "Something old, something new…". Ann Gastroenterol (2016) 0.75
Evaluating the Significance of Viscoelasticity in Diagnosing Early-Stage Liver Fibrosis with Transient Elastography. PLoS One (2017) 0.75
Task-based optimization of flip angle for fibrosis detection in T1-weighted MRI of liver. J Med Imaging (Bellingham) (2016) 0.75
Combining immunodetection with histochemical techniques: the effect of heat-induced antigen retrieval on picro-Sirius red staining. J Histochem Cytochem (2014) 0.75
An analysis of intrinsic variations of low-frequency shear wave speed in a stochastic tissue model: the first application for staging liver fibrosis. Phys Med Biol (2017) 0.75
Histological grading and staging of chronic hepatitis. J Hepatol (1995) 19.57
A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology (2003) 16.40
Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol (1999) 14.07
An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology (1996) 12.47
Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology (1982) 11.24
Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology (2003) 10.25
Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet (1997) 10.05
Liver biopsy. N Engl J Med (2001) 9.91
Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology (1994) 9.86
Prospective comparison of transient elastography, Fibrotest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology (2005) 9.44
Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol (2003) 9.19
Identification of chronic hepatitis C patients without hepatic fibrosis by a simple predictive model. Hepatology (2002) 6.92
Serum markers detect the presence of liver fibrosis: a cohort study. Gastroenterology (2004) 6.14
Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology (2005) 5.93
Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet (2001) 5.82
Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease. J Hepatol (2003) 5.17
Histological outcome during long-term lamivudine therapy. Gastroenterology (2003) 3.88
A comparison of fibrosis progression in chronic liver diseases. J Hepatol (2003) 2.82
Sources of variability in histological scoring of chronic viral hepatitis. Hepatology (2005) 2.64
Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest, HCV FibroSure) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol (2004) 2.19
Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver (1999) 2.01
The normal adult human liver biopsy: a quantitative reference standard. Hepatology (1998) 1.60
Reversibility of hepatic fibrosis in autoimmune hepatitis. Ann Intern Med (1997) 1.54
Intra-observer and inter-observer variation in the histopathological assessment of chronic viral hepatitis. J Hepatol (1996) 1.44
Identification of chronic hepatitis B patients without significant liver fibrosis by a simple noninvasive predictive model. Am J Gastroenterol (2005) 1.33
Guided versus blind liver biopsy for chronic hepatitis C: clinical benefits and costs. J Hepatol (1999) 1.26
Scoring of chronic hepatitis. Clin Liver Dis (2002) 1.25
Sampling variability on percutaneous liver biopsy in patients with chronic hepatitis C virus infection. Scand J Gastroenterol (2003) 1.23
Histopathological evaluation of liver fibrosis: quantitative image analysis vs semi-quantitative scores. Comparison with serum markers. J Hepatol (1998) 1.23
Automatic quantification of liver fibrosis: design and validation of a new image analysis method: comparison with semi-quantitative indexes of fibrosis. J Hepatol (2000) 1.15
Long-term evolution of fibrosis from chronic hepatitis to cirrhosis in patients with hepatitis C: morphometric analysis of repeated biopsies. Hepatology (1997) 1.12
Histological changes in liver biopsies after one year of lamivudine treatment in patients with chronic hepatitis B infection. J Hepatol (1999) 1.12
Liver biopsy: review of methodology and complications. Dig Dis (1996) 1.10
An assessment of digital image analysis to measure fibrosis in liver biopsy specimens of patients with chronic hepatitis C. Am J Clin Pathol (2000) 1.07
Regression of hepatic fibrosis in hepatitis C with long-term interferon treatment. Dig Dis Sci (1998) 1.05
Transjugular liver biopsy in 52 patients with an automated Trucut-type needle. Dig Dis Sci (1999) 1.03
Sirius red histophotometry and spectrophotometry of sections in the assessment of the collagen content of liver tissue and its application in growing rat liver. Liver (1990) 1.00
Diagnosis of chronic liver disease: reproducibility and validation of liver biopsy. Am J Gastroenterol (2002) 1.00
The extracellular matrix of the liver. Coll Relat Res (1982) 0.97
Noninvasive markers of fibrosis for longitudinal assessment of fibrosis in chronic liver disease: are they ready for prime time? Am J Gastroenterol (2005) 0.96
Transjugular liver biopsy with an automated trucut-type needle: comparative study with percutaneous liver biopsy. Eur J Gastroenterol Hepatol (2002) 0.96
Transjugular liver biopsy in the 1990s: a 2-year audit. Aliment Pharmacol Ther (1999) 0.95
Quantitative versus morphological assessment of liver fibrosis: semi-quantitative scores are more robust than digital image fibrosis area estimation. Liver Int (2003) 0.94
Assessing fibrosis without a liver biopsy: are we there yet? Gastroenterology (2004) 0.93
Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int (2005) 0.91
Hydroxyproline content of needle biopsies as an objective measure of liver fibrosis: Emphasis on sampling variability. J Gastroenterol Hepatol (2005) 0.90
Interferon-alpha 2b therapy reduces liver fibrosis in chronic non-A, non-B hepatitis: a quantitative histological evaluation. Hepatology (1993) 0.90
Quantitative assessment of fibrosis in liver biopsies from patients with chronic hepatitis B. Liver Int (2004) 0.90
Transjugular liver biopsy: a review of 200 biopsies. Clin Radiol (1992) 0.89
Liver fibrosis and extracellular matrix. J Hepatol (1989) 0.87
Blinded comparison of biopsy needles and automated devices in vitro: 1. Biopsy of diffuse hepatic disease. AJR Am J Roentgenol (1993) 0.85
Influence of operator experience on performance of ultrasound-guided percutaneous liver biopsy. Eur Radiol (2004) 0.84
Treatment of histologically mild hepatitis C virus infection with interferon and ribavirin: a multicentre randomized controlled trial. J Viral Hepat (2005) 0.84
Large-needle biopsy versus thin-needle biopsy in diagnostic pathology of liver diseases. Liver (2001) 0.84
Are picro-dye reactions for collagens quantitative? Chemical and histochemical considerations. Histochemistry (1988) 0.83
Transjugular liver biopsy is safe and diagnostic for patients with congenital bleeding disorders and hepatitis C infection. Haemophilia (2003) 0.83
Critical analysis of the methods used to morphologically quantify hepatic fibrosis. J Hepatol (1995) 0.82
Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method. J Hepatol (1998) 0.78
Liver fibrosis: natural history may be affected by the biopsy sample. Gut (2004) 0.78
[Is percutaneous liver biopsy using the Trucut (Travenol) needle superior to Menghini puncture?]. Z Gastroenterol (1989) 0.77
Retracted Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet (1998) 36.93
Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol (2001) 19.07
International Autoimmune Hepatitis Group Report: review of criteria for diagnosis of autoimmune hepatitis. J Hepatol (1999) 9.11
Pathogenesis of Crohn's disease: multifocal gastrointestinal infarction. Lancet (1989) 5.70
Carcinoid tumour. Lancet (1998) 4.52
Nine scoring models for short-term mortality in alcoholic hepatitis: cross-validation in a biopsy-proven cohort. Aliment Pharmacol Ther (2014) 3.98
Hepatocytes from non-hepatic adult stem cells. Nature (2000) 3.27
Seeding following percutaneous diagnostic and therapeutic approaches for hepatocellular carcinoma. What is the risk and the outcome? Seeding risk for percutaneous approach of HCC. Cancer Treat Rev (2007) 2.75
Granulomatous vasculitis in Crohn's disease. Gastroenterology (1991) 2.72
Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut (2000) 2.55
Hepatic angiomyolipoma: a clinicopathologic study of 30 cases and delineation of unusual morphologic variants. Am J Surg Pathol (1999) 2.53
Elastography for the diagnosis of severity of fibrosis in chronic liver disease: a meta-analysis of diagnostic accuracy. J Hepatol (2010) 2.50
PGP 9.5--a new marker for vertebrate neurons and neuroendocrine cells. Brain Res (1983) 2.41
Anti-tuberculosis medication and the liver: dangers and recommendations in management. Eur Respir J (1995) 2.39
Bacterial infection in the pathogenesis of variceal bleeding. Lancet (1999) 2.35
The Eurotransplant donor risk index in liver transplantation: ET-DRI. Am J Transplant (2012) 2.29
Review article: nucleos(t)ide analogues in patients with chronic hepatitis B virus infection and chronic kidney disease. Aliment Pharmacol Ther (2013) 2.22
An evaluation of emergency sclerotherapy of varices in randomized trials: looking the needle in the eye. Endoscopy (2006) 2.22
Coagulation and fibrosis in chronic liver disease. Gut (2008) 2.22
Systematic review and meta-analysis of intraoperative versus preoperative endoscopic sphincterotomy in patients with gallbladder and suspected common bile duct stones. Br J Surg (2011) 2.13
Controlled trial of propranolol for the prevention of recurrent variceal hemorrhage in patients with cirrhosis. N Engl J Med (1983) 2.10
Interobserver study of liver histopathology using the Ishak score in patients with chronic hepatitis C virus infection. Liver (1999) 2.01
Risk factors, sequential organ failure assessment and model for end-stage liver disease scores for predicting short term mortality in cirrhotic patients admitted to intensive care unit. Aliment Pharmacol Ther (2006) 2.00
Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet (1999) 1.98
PGP 9.5, a new marker for human neuroendocrine tumours. Histopathology (1985) 1.97
"Salvage" transjugular intrahepatic portosystemic shunts: gastric fundal compared with esophageal variceal bleeding. Gastroenterology (1998) 1.95
Transjugular intrahepatic portosystemic shunt versus endoscopic therapy: randomized trials for secondary prophylaxis of variceal bleeding: an updated meta-analysis. Scand J Gastroenterol (2002) 1.92
A randomized, controlled trial of medical therapy versus endoscopic ligation for the prevention of variceal rebleeding in patients with cirrhosis. Gastroenterology (2002) 1.90
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis? Aliment Pharmacol Ther (2005) 1.86
Core promoter mutations and genotypes in relation to viral replication and liver damage in East Asian hepatitis B virus carriers. J Infect Dis (1999) 1.84
Proposal for standardized criteria for the diagnosis of benign, borderline, and malignant hepatocellular lesions arising in chronic advanced liver disease. Am J Surg Pathol (1993) 1.84
Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet (1996) 1.78
Evidence of persistent measles virus infection in Crohn's disease. J Med Virol (1993) 1.76
A predictive model for failure to control bleeding during acute variceal haemorrhage. J Hepatol (1999) 1.76
QBEnd/10: a new immunostain for the routine diagnosis of Kaposi's sarcoma. J Pathol (1990) 1.76
Change in occurrence of paracetamol overdose in UK after introduction of blister packs. Lancet (2000) 1.75
Portal hypertension and variceal bleeding: an AASLD single topic symposium. Hepatology (1998) 1.74
Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol (1996) 1.73
Prevention of first bleeding in cirrhosis. A meta-analysis of randomized trials of nonsurgical treatment. Ann Intern Med (1992) 1.72
The immunolocalization of protein gene product 9.5 using rabbit polyclonal and mouse monoclonal antibodies. Br J Exp Pathol (1988) 1.67
Macrophage heterogeneity in normal colonic mucosa and in inflammatory bowel disease. Gut (1988) 1.67
Ulcerative colitis has an aggressive course after orthotopic liver transplantation for primary sclerosing cholangitis. Gut (1998) 1.63
Treatment outcomes for hepatocellular carcinoma using chemoembolization in combination with other therapies. Cancer Treat Rev (2006) 1.63
Enhanced thrombin generation in patients with cirrhosis-induced coagulopathy. J Thromb Haemost (2010) 1.62
Transjugular liver biopsy: how good is it for accurate histological interpretation? Gut (2006) 1.61
Disseminated intravascular coagulation in liver cirrhosis: fact or fiction? Am J Gastroenterol (1999) 1.60
Review article: portal vein thrombosis -- new insights into aetiology and management. Aliment Pharmacol Ther (2005) 1.59
Methotrexate and liver fibrosis in people with psoriasis: a systematic review of observational studies. Br J Dermatol (2014) 1.57
Bacterial infection is independently associated with failure to control bleeding in cirrhotic patients with gastrointestinal hemorrhage. Hepatology (1998) 1.57
Biochemical criteria at 1 year are not robust indicators of response to ursodeoxycholic acid in early primary biliary cirrhosis: results from a 29-year cohort study. Aliment Pharmacol Ther (2013) 1.56
Azathioprine in liver transplantation: a reevaluation of its use and a comparison with mycophenolate mofetil. Am J Transplant (2009) 1.52
Hepatocellular carcinoma arising in an adenoma: value of QBend 10 immunostaining in diagnosis of liver cell carcinoma. Histopathology (1996) 1.49
Small hepatocellular carcinomas in cirrhotic explant livers: identification by macroscopic examination and lipiodol localization. Hepatology (1997) 1.48
Diurnal pattern of variceal bleeding in cirrhotic patients. J Hepatol (1993) 1.47
Randomized controlled trial of tacrolimus versus microemulsified cyclosporin (TMC) in liver transplantation: poststudy surveillance to 3 years. Am J Transplant (2006) 1.47
Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis. Aliment Pharmacol Ther (2011) 1.46
Review article: renal function assessment in cirrhosis - difficulties and alternative measurements. Aliment Pharmacol Ther (2007) 1.45
Update of the International Banff Schema for Liver Allograft Rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An International Panel. Hepatology (2000) 1.44
Genomic heterogeneity in synchronous hepatocellular carcinomas. Gut (1999) 1.44
Hepatitis B virus DNA levels, precore mutations, genotypes and histological activity in chronic hepatitis B. J Viral Hepat (2000) 1.43
Tacrolimus exposure after liver transplantation in randomized controlled trials: too much for too long. Am J Transplant (2013) 1.40
Review article: the pharmacological implications of leucocyte-endothelial cell interactions in Crohn's disease. Aliment Pharmacol Ther (1991) 1.40
Systematic review of radiological imaging for hepatocellular carcinoma in cirrhotic patients. Br J Radiol (2004) 1.40
Infection, coagulation, and variceal bleeding in cirrhosis. Gut (2005) 1.39
Staple-line erosion: a common source of recurrent bleeding following stapled oesophageal transection. Br J Surg (1991) 1.39
Vascular invasion and herniation by hepatocellular carcinoma in cirrhosis: A wolf in sheep's clothing? Arch Pathol Lab Med (2005) 1.39
Ultrasound screening for hepatocellular carcinoma (HCC) in cirrhosis: the evidence for an established clinical practice. Clin Radiol (1998) 1.38
LeVeen shunt with wandering tip. Lancet (1991) 1.36
Idiopathic acute fatty liver of pregnancy in 12 patients. Q J Med (1982) 1.36
Kinetics of cytomegalovirus load decrease in solid-organ transplant recipients after preemptive therapy with valganciclovir. J Infect Dis (2004) 1.35
Systematic review: portal vein thrombosis in cirrhosis. Aliment Pharmacol Ther (2009) 1.35
Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J Hepatol (2007) 1.33
Controversies in the management of bleeding esophageal varices (1) N Engl J Med (1989) 1.30
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis. Hepatology (1999) 1.29
Neurone specific enolase: an aid to the diagnosis of melanoma and neuroblastoma. Histopathology (1982) 1.27
Definitions, methodology and therapeutic strategies in portal hypertension. A Consensus Development Workshop, Baveno, Lake Maggiore, Italy, April 5 and 6, 1990. J Hepatol (1992) 1.27
Female liver transplant recipients with the same GFR as male recipients have lower MELD scores--a systematic bias. Am J Transplant (2007) 1.25
Endoscopic extraction of bile duct stones: management related to stone size. Gut (1993) 1.24
Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. J Viral Hepat (2002) 1.22
Bacteriuria and primary biliary cirrhosis. Gut (1984) 1.20
Cytomegalovirus replication kinetics in solid organ transplant recipients managed by preemptive therapy. Am J Transplant (2012) 1.19
Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet (1994) 1.18
The value of rectal biopsy in distinguishing self-limited colitis from early inflammatory bowel disease. Q J Med (1987) 1.18
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer (2013) 1.17
New insights into the coagulopathy of liver disease and liver transplantation. World J Gastroenterol (2006) 1.17
Review article: scoring systems for assessing prognosis in critically ill adult cirrhotics. Aliment Pharmacol Ther (2006) 1.17
Early mucosal changes in Crohn's disease. Gut (1993) 1.16
Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther (2006) 1.15
Hepatic artery thrombosis after orthotopic liver transplantation: a review of nonsurgical causes. Liver Transpl (2001) 1.15
Should we biopsy each liver mass suspicious for HCC before liver transplantation?--no, please don't. J Hepatol (2005) 1.15
Distal spleno-renal shunt versus endoscopic sclerotherapy in the prevention of variceal rebleeding. A meta-analysis of 4 randomized clinical trials. J Hepatol (1992) 1.14
Controversies in the management of bleeding esophageal varices (2) N Engl J Med (1989) 1.14
Treatment of small hepatocellular carcinomas. Lancet (1992) 1.13
In vivo and in vitro hepatic 31P magnetic resonance spectroscopy and electron microscopy of the cirrhotic liver. Liver (1997) 1.13